Abstract
BackgroundKirsten ras oncogene homolog (KRAS)-G12C allele-specific mutations are majorly observed in about 15% of non-small cell lung cancer (NSCLC) and about 3% of colorectal cancers. KRAS mutation-specific inhibitors have had...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
